CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--DiaKine Therapeutics, Inc., a developer of drugs designed to treat diabetes and other immune-related diseases via a novel approach, today announced the appointment of Dr. Alexander “Zan” Fleming to its Scientific Advisory Board.
